Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer

Biomaterials

Volumn 99, Issue , 2016, Pages 1-15

  Yeh, Chen Yun ^a,b   Hsiao, Jong Kai ^c,d   Wang, Yi Ping ^b,e   Lan, Chun Hsin ^b   Wu, Han Chung ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c TAIPEI TZU CHI HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Drug delivery systems; Molecular imaging; Peptide conjugated nanoparticles; Phage display; Prostate cancer

Indexed keywords

BIOLOGICAL MATERIALS; CELL CULTURE; CELLS; CLONE CELLS; CYTOLOGY; ENZYME INHIBITION; LIPOSOMES; MOLECULAR IMAGING; NANOPARTICLES; PEPTIDES; SEMICONDUCTOR QUANTUM DOTS; TUMORS; UROLOGY;

CONJUGATED LIPOSOMES; DRUG DELIVERY SYSTEM; INTRACELLULAR DELIVERY; LIPOSOMAL DOXORUBICIN; PHAGE DISPLAY; PROSTATE CANCER CELLS; PROSTATE CANCERS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

DISEASES;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DOCETAXEL; DOXORUBICIN; LIPOSOME; MACROGOL; NANOPARTICLE; NAVELBINE; PEPTIDE; PEPTIDE CONJUGATED NANOPARTICLE; PEPTIDE PC204; PEPTIDE SP204 CONJUGATED LIPOSOMAL DOXORUBICIN; PEPTIDE SP204 CONJUGATED LIPOSOMAL VINORELBINE; PEPTIDE SP204 CONJUGATED QUANTUM DOT; PEPTIDE SP204 CONJUGATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; FERRIC ION; FERRIC OXIDE; MACROGOL DERIVATIVE; METAL NANOPARTICLE; VINBLASTINE; VINORELBINE TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLUMINESCENCE; BIOPANNING; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TUMOR LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEDIAN SURVIVAL TIME; MOLECULAR IMAGING; MOUSE; MTT ASSAY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEK293 CELL LINE; MALE; PARTICLE SIZE; PEPTIDE LIBRARY; PROSTATE TUMOR; SCID MOUSE; SURFACE PROPERTY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CONTRAST MEDIA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HEK293 CELLS; HUMANS; LIPOSOMES; MALE; METAL NANOPARTICLES; MICE, SCID; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; PEPTIDE LIBRARY; PEPTIDES; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; SURFACE PROPERTIES; TISSUE DISTRIBUTION; VINBLASTINE;

EID: 84969724132     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.05.015     Document Type: Article

References (51)

1. Mariotto A.B., Yabroff K.R., Shao Y., Feuer E.J., Brown M.L. Projections of the cost of cancer care in the United States: 2010-2020. J. Natl. Cancer Inst. 2011, 103:117-128.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65:5-29.
3. Suzman D.L., Antonarakis E.S. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol. 2014, 6:167-179.
4. Chang A.J., Autio K.A., Roach M., Scher H.I. High-risk prostate cancer-classification and therapy. Nat. Rev. Clin. Oncol. 2014, 11:308-323.
5. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008, 8:440-448.
6. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003, 349:366-381.
7. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
8. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
9. Lorente D., Mateo J., Perez-Lopez R., de Bono J.S., Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol. 2015, 16:e279-e292.
10. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
11. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987, 47:3039-3051.
12. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
13. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
14. Nehoff H., Parayath N.N., Domanovitch L., Taurin S., Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomed. 2014, 9:2539-2555.
15. Baronzio G., Parmar G., Baronzio M. Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid. Front. Oncol. 2015, 5:165.
16. Wu C.H., Kuo Y.H., Hong R.L., Wu H.C. alpha-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Sci. Transl. Med. 2015, 7:290-291.
17. Wu C.H., Liu I.J., Lu R.M., Wu H.C. Advancement and applications of peptide phage display technology in biomedical science. J. Biomed. Sci. 2016, 23:8.
18. Lu R.M., Chen M.S., Chang D.K., Chiu C.Y., Lin W.C., Yan S.L., et al. Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. PLoS One 2013, 8:e66128.
19. Lu R.M., Chang Y.L., Chen M.S., Wu H.C. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32:3265-3274.
20. Laginha K.M., Verwoert S., Charrois G.J., Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin. Cancer Res. 2005, 11:6944-6949.
21. Aziz M.H., Dreckschmidt N.E., Verma A.K. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008, 68:9024-9032.
22. Chang D.K., Chiu C.Y., Kuo S.Y., Lin W.C., Lo A., Wang Y.P., et al. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J. Biol. Chem. 2009, 284:12905-12916.
23. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
24. Smith M.A., Seibel N.L., Altekruse S.F., Ries L.A., Melbert D.L., O'Leary M., et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J. Clin. Oncol. 2010, 28:2625-2634.
25. Stegemann S., Leveiller F., Franchi D., de Jong H., Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 2007, 31:249-261.
26. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12:39-50.
27. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010, 5:597-615.
28. Zhang J., Li X., Huang L. Non-viral nanocarriers for siRNA delivery in breast cancer. J. Control Release 2014, 190:440-450.
29. Deeken J.F., Slack R., Weiss G.J., Ramanathan R.K., Pishvaian M.J., Hwang J., et al. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother. Pharmacol. 2013, 71:627-633.
30. Wu H.C., Chang D.K. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J. Oncol. 2010, 2010:723798.
31. Fernandes E., Ferreira J.A., Andreia P., Luis L., Barroso S., Sarmento B., et al. New trends in guided nanotherapies for digestive cancers: a systematic review. J. Control Release 2015, 209:288-307.
32. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25:3389-3402.
33. Tan M.H., Li J., Xu H.E., Melcher K., Yong E.L. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 2015, 36:3-23.
34. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
35. Deng Q., Tang D.G. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr. Relat. Cancer 2015, 22:T209-T220.
36. Pectasides D., Pectasides E., Papaxoinis G., Koumarianou A., Psyrri A., Xiros N., et al. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. Anticancer Res. 2009, 29:769-775.
37. Firer M.A., Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol. 2012, 5:70.
38. Bulte J.W., Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004, 17:484-499.
39. Thomas R., Park I.K., Jeong Y.Y. Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer. Int. J. Mol. Sci. 2013, 14:15910-15930.
40. Kievit F.M., Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res. 2011, 44:853-862.
41. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
42. Irollo E., Pirozzi G. CD133: to be or not to be, is this the real question?. Am. J. Transl. Res. 2013, 5:563-581.
43. Iida H., Suzuki M., Goitsuka R., Ueno H. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int. J. Oncol. 2012, 40:71-79.
44. Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J.V., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 2012, 12:767-775.
45. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Investig. 2010, 120:41-50.
46. Patriarca C., Macchi R.M., Marschner A.K., Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev. 2012, 38:68-75.
47. Ni J., Cozzi P., Hao J., Beretov J., Chang L., Duan W., et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int. J. Biochem. Cell Biol. 2013, 45:2736-2748.
48. Carvalho F.L., Simons B.W., Antonarakis E.S., Rasheed Z., Douglas N., Villegas D., et al. Tumorigenic potential of circulating prostate tumor cells. Oncotarget 2013, 4:413-421.
49. Jost M., Day J.R., Slaughter R., Koreckij T.D., Gonzales D., Kinnunen M., et al. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol. Cancer 2010, 9:174.
50. Armstrong A.J., Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9:997-1007.
51. Zhu Y., Sun Y., Chen Y., Liu W., Jiang J., Guan W., et al. In vivo molecular MRI imaging of prostate cancer by targeting PSMA with polypeptide-labeled superparamagnetic iron oxide nanoparticles. Int. J. Mol. Sci. 2015, 16:9573-9587.